Shortened tuberculosis treatment regimens: what is new?

Given the global burden of tuberculosis, shortened treatment regimens with existing or repurposed drugs are needed to contribute to tuberculosis control. The long duration of treatment of drug-susceptible tuberculosis (DS-TB) is associated with nonadherence and loss to follow up, and the treatment s...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Jornal brasileiro de pneumologia Jg. 46; H. 2; S. e20200009
Hauptverfasser: Rossato Silva, Denise, Carvalho de Queiroz Mello, Fernanda, Battista Migliori, Giovanni
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Brazil Sociedade Brasileira de Pneumologia e Tisiologia 2020
Schlagworte:
Drug resistance, bacterial
RESPIRATORY SYSTEM
Review
Tuberculosis, multidrug-resistant/drug therapy
Tuberculosis/drug therapy
Tuberculose/tratamento farmacológico
Farmacorresistência bacteriana
Tuberculose resistente a múltiplos medicamentos/tratamento farmacológico
Drug resistance, bacterial
Tuberculosis/drug therapy
Tuberculosis, multidrug-resistant/drug therapy
ISSN:1806-3756, 1806-3713, 1806-3756
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Given the global burden of tuberculosis, shortened treatment regimens with existing or repurposed drugs are needed to contribute to tuberculosis control. The long duration of treatment of drug-susceptible tuberculosis (DS-TB) is associated with nonadherence and loss to follow up, and the treatment success rate of multidrug-resistant tuberculosis (MDR-TB) is low (approximately 50%) with longer regimens. In this review article, we report recent advances and ongoing clinical trials aimed at shortening regimens for DS-TB and MDR-TB. We discuss the role of high-dose rifampin, as well as that of clofazimine and linezolid in regimens for DS-TB. There are at least 5 ongoing clinical trials and 17 observational studies and clinical trials evaluating shorter regimens for DS-TB and MDR-TB, respectively. We also report the results of observational studies and clinical trials evaluating a standardized nine-month moxifloxacin-based regimen for MDR-TB. Further studies, especially randomized clinical trials, are needed to evaluate regimens including newer drugs, drugs proven to be or highly likely to be efficacious, and all-oral drugs in an effort to eliminate the need for injectable drugs.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1806-3756
1806-3713
1806-3756
DOI:10.36416/1806-3756/e20200009